{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T15:57:26Z","timestamp":1775923046629,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004357","name":"Procter and Gamble","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016730","name":"Torii Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21gm1210006"],"award-info":[{"award-number":["JP21gm1210006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jid.2021.09.023","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T21:53:10Z","timestamp":1637185990000},"page":"47-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A New Era with the Development of Cytokine-Based Therapy for Pruritus"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3805-2562","authenticated-orcid":false,"given":"Rintaro","family":"Shibuya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6038-7815","authenticated-orcid":false,"given":"Riko","family":"Takimoto-Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-4952","authenticated-orcid":false,"given":"Naotomo","family":"Kambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0554","authenticated-orcid":false,"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.09.023_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamadermatol.2018.3912","article-title":"Dupilumab treatment for generalized prurigo Nodularis","volume":"155","author":"Beck","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.09.023_bib3","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/exd.14034","article-title":"Interleukin-4 and interleukin-13 evoke scratching behaviour in mice","volume":"28","author":"Campion","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A\u00a0sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib5","doi-asserted-by":"crossref","first-page":"e13606","DOI":"10.1111\/dth.13606","article-title":"When life is an itch: what harms, helps, and heals from the patients' perspective? Differences and similarities among skin diseases","volume":"33","author":"Chee","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.09.023_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2021.09.023_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejcb.2011.07.006","article-title":"Signaling by IL-31 and functional consequences","volume":"91","author":"Cornelissen","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.jid.2021.09.023_bib8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","article-title":"IL-31 regulates differentiation and filaggrin expression in human organotypic skin models","volume":"129","author":"Cornelissen","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib9","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice [published correction appears in Nat Immunol 2004;6:114]","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib11","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3347","article-title":"A\u00a0new generation of treatments for itch","volume":"100","author":"Fowler","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.09.023_bib12","doi-asserted-by":"crossref","first-page":"e13201","DOI":"10.1111\/dth.13201","article-title":"Efficacy of dupilumab in prurigo nodularis in elderly patient","volume":"33","author":"Giura","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.09.023_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib14","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.09.023_bib15","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.4049\/jimmunol.1402943","article-title":"Control of the physical and antimicrobial skin barrier by an IL-31-IL-1 signaling network","volume":"196","author":"H\u00e4nel","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaad.2020.08.035","article-title":"The characteristics and impact of pruritus in adult dermatology patients: a prospective, cross-sectional study","volume":"84","author":"Hawro","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.jid.2021.09.023_bib17","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2019.08.006","article-title":"Interleukin-33 in atopic dermatitis","volume":"96","author":"Imai","year":"2019","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2021.09.023_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ijd.14081","article-title":"Itch and psyche: psychiatric aspects of pruritus","volume":"58","author":"Jafferany","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib21","doi-asserted-by":"crossref","first-page":"638325","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jid.2021.09.023_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.09.023_bib23","doi-asserted-by":"crossref","first-page":"170ra16","DOI":"10.1126\/scitranslmed.3005374","article-title":"TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation","volume":"5","author":"Kim","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2021.09.023_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: the skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib25","doi-asserted-by":"crossref","first-page":"E7572","DOI":"10.1073\/pnas.1606608113","article-title":"IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy","volume":"113","author":"Liu","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2021.09.023_bib62","first-page":"124","article-title":"Serum interleukin-31 level and pruritus in atopic dermatitis: a meta-analysis","volume":"43","author":"Lu","year":"2018","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.jid.2021.09.023_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jid.2019.07.711","article-title":"The annual direct and indirect health care costs for patients with chronic pruritus and their determining factors","volume":"140","author":"Luk","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib27","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","article-title":"The itch-scratch cycle: a neuroimmune perspective","volume":"39","author":"Mack","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib28","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/jdv.15947","article-title":"Comments to the letter to the editor by Dr Sweta Subhadarshani","volume":"34","author":"Naafs","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.09.023_bib61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.alit.2020.01.001","article-title":"Anti-TSLP antibodies: targeting a\u00a0master regulator of type 2 immune responses","volume":"69","author":"Nakajima","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jid.2021.09.023_bib63","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib31","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.4049\/jimmunol.0900712","article-title":"Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells","volume":"184","author":"Niyonsaba","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jid.2021.09.023_bib33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2021.09.023_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are\u00a0a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2021.09.023_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2020.08.059","article-title":"Sleep disturbance in adults with chronic pruritic dermatoses is associated with increased C-reactive protein levels","volume":"84","author":"Patel","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2500\/aap.2018.38.4105","article-title":"Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and\/or immunoglobulin E","volume":"39","author":"Petra","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jid.2021.09.023_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cea.12875","article-title":"Human basophils are a source of - and are differentially activated by - IL-31","volume":"47","author":"Raap","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jid.2021.09.023_bib39","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.09.023_bib40","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib42","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib43","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the International Forum for the Study of Itch","volume":"87","author":"St\u00e4nder","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.09.023_bib47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.09.023_bib48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0625.2012.01487.x","article-title":"Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin","volume":"21","author":"Szegedi","year":"2012","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.16934","article-title":"Atopic dermatitis: the skin barrier and beyond","volume":"180","author":"Tsakok","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nn.3881","article-title":"Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing","volume":"18","author":"Usoskin","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jid.2021.09.023_bib51","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.immuni.2020.04.008","article-title":"Itch: a paradigm of neuroimmune crosstalk","volume":"52","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2021.09.023_bib52","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamadermatol.2019.2804","article-title":"Treatment of refractory chronic pruritus of unknown origin with tofacitinib in patients with rheumatoid arthritis","volume":"155","author":"Wang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib53","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaad.2020.06.1002","article-title":"Emergency department use by patients with prurigo nodularis in the United States","volume":"84","author":"Whang","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib54","first-page":"88","article-title":"Inpatient burden of prurigo nodularis in the United States","volume":"6","author":"Whang","year":"2019","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.jid.2021.09.023_bib55","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jid.2020.08.020","article-title":"Health-related QOL and economic burden of chronic pruritus","volume":"141","author":"Whang","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.09.023_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jid.2021.09.023_bib57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.09.023_bib58","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/ijms18071485","article-title":"Inflammatory and noninflammatory itch: implications in pathophysiology-directed treatments","volume":"18","author":"Wong","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2021.09.023_bib59","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/ijms21082867","article-title":"Skin barrier abnormalities and immune dysfunction in atopic dermatitis","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2021.09.023_bib60","doi-asserted-by":"crossref","first-page":"107830","DOI":"10.1016\/j.pharmthera.2021.107830","article-title":"Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials","volume":"224","author":"Yang","year":"2021","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21023460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21023460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:22:37Z","timestamp":1758302557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21023460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0022202X21023460"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.09.023","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A New Era with the Development of Cytokine-Based Therapy for Pruritus","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}